NCT02853331 2026-02-02KEYNOTE-426Merck Sharp & Dohme LLCPhase 3 Completed861 enrolled 24 charts 1 FDA
NCT04585815 2026-01-09Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)PfizerPhase 1/2 Terminated34 enrolled 44 charts